CD274, an important immunotherapeutic target, has achieved good results in non-small cell lung cancer, colorectal cancer and melanoma, and has also demonstrated prolonged overall survival in several phase II clinical trials in glioma (38). This evidence concerns the gene CD274 and central nervous system cancer.